137 related articles for article (PubMed ID: 25997147)
1. A high ratio of IC31(®) adjuvant to antigen is necessary for H4 TB vaccine immunomodulation.
Aboutorabian S; Hakimi J; Boudet F; Montano S; Dookie A; Roque C; Ausar SF; Rahman N; Brookes RH
Hum Vaccin Immunother; 2015; 11(6):1449-55. PubMed ID: 25997147
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials.
Norrby M; Vesikari T; Lindqvist L; Maeurer M; Ahmed R; Mahdavifar S; Bennett S; McClain JB; Shepherd BM; Li D; Hokey DA; Kromann I; Hoff ST; Andersen P; de Visser AW; Joosten SA; Ottenhoff THM; Andersson J; Brighenti S
Vaccine; 2017 Mar; 35(12):1652-1661. PubMed ID: 28216183
[TBL] [Abstract][Full Text] [Related]
3. Tuberculosis vaccine candidate: Characterization of H4-IC31 formulation and H4 antigen conformation.
Deshmukh SS; Magcalas FW; Kalbfleisch KN; Carpick BW; Kirkitadze MD
J Pharm Biomed Anal; 2018 Aug; 157():235-243. PubMed ID: 29866391
[TBL] [Abstract][Full Text] [Related]
4. The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial.
Geldenhuys H; Mearns H; Miles DJ; Tameris M; Hokey D; Shi Z; Bennett S; Andersen P; Kromann I; Hoff ST; Hanekom WA; Mahomed H; Hatherill M; Scriba TJ; ; van Rooyen M; Bruce McClain J; Ryall R; de Bruyn G;
Vaccine; 2015 Jul; 33(30):3592-9. PubMed ID: 26048780
[TBL] [Abstract][Full Text] [Related]
5. Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection.
van Dissel JT; Soonawala D; Joosten SA; Prins C; Arend SM; Bang P; Tingskov PN; Lingnau K; Nouta J; Hoff ST; Rosenkrands I; Kromann I; Ottenhoff TH; Doherty TM; Andersen P
Vaccine; 2011 Mar; 29(11):2100-9. PubMed ID: 21256189
[TBL] [Abstract][Full Text] [Related]
6. First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults.
Luabeya AK; Kagina BM; Tameris MD; Geldenhuys H; Hoff ST; Shi Z; Kromann I; Hatherill M; Mahomed H; Hanekom WA; Andersen P; Scriba TJ; ; Schoeman E; Krohn C; Day CL; Africa H; Makhethe L; Smit E; Brown Y; Suliman S; Hughes EJ; Bang P; Snowden MA; McClain B; Hussey GD
Vaccine; 2015 Aug; 33(33):4130-40. PubMed ID: 26095509
[TBL] [Abstract][Full Text] [Related]
7. Flow cytometry: An efficient method for antigenicity measurement and particle characterization on an adjuvanted vaccine candidate H4-IC31 for tuberculosis.
He L; Su J; Ming M; Bernardo L; Chen T; Gisonni-Lex L; Gajewska B
J Immunol Methods; 2018 Jan; 452():39-45. PubMed ID: 29056527
[TBL] [Abstract][Full Text] [Related]
8. An in vitro functional assay to measure the biological activity of TB vaccine candidate H4-IC31.
Ming M; Bernardo L; Williams K; Kolattukudy P; Kapoor N; Chan LG; Pagnon A; Piras F; Su J; Gajewska B; Salha D; Gisonni-Lex L
Vaccine; 2019 May; 37(22):2960-2966. PubMed ID: 31010716
[TBL] [Abstract][Full Text] [Related]
9. Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen.
Skeiky YA; Dietrich J; Lasco TM; Stagliano K; Dheenadhayalan V; Goetz MA; Cantarero L; Basaraba RJ; Bang P; Kromann I; McMclain JB; Sadoff JC; Andersen P
Vaccine; 2010 Jan; 28(4):1084-93. PubMed ID: 19896449
[TBL] [Abstract][Full Text] [Related]
10. Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31.
Agger EM; Rosenkrands I; Olsen AW; Hatch G; Williams A; Kritsch C; Lingnau K; von Gabain A; Andersen CS; Korsholm KS; Andersen P
Vaccine; 2006 Jun; 24(26):5452-60. PubMed ID: 16675077
[TBL] [Abstract][Full Text] [Related]
11. H1:IC31 vaccination is safe and induces long-lived TNF-α
Mearns H; Geldenhuys HD; Kagina BM; Musvosvi M; Little F; Ratangee F; Mahomed H; Hanekom WA; Hoff ST; Ruhwald M; Kromann I; Bang P; Hatherill M; Andersen P; Scriba TJ;
Vaccine; 2017 Jan; 35(1):132-141. PubMed ID: 27866772
[TBL] [Abstract][Full Text] [Related]
12. Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination.
Nemes E; Geldenhuys H; Rozot V; Rutkowski KT; Ratangee F; Bilek N; Mabwe S; Makhethe L; Erasmus M; Toefy A; Mulenga H; Hanekom WA; Self SG; Bekker LG; Ryall R; Gurunathan S; DiazGranados CA; Andersen P; Kromann I; Evans T; Ellis RD; Landry B; Hokey DA; Hopkins R; Ginsberg AM; Scriba TJ; Hatherill M;
N Engl J Med; 2018 Jul; 379(2):138-149. PubMed ID: 29996082
[TBL] [Abstract][Full Text] [Related]
13. The two-component adjuvant IC31® boosts type i interferon production of human monocyte-derived dendritic cells via ligation of endosomal TLRs.
Szabo A; Gogolak P; Pazmandi K; Kis-Toth K; Riedl K; Wizel B; Lingnau K; Bacsi A; Rethi B; Rajnavolgyi E
PLoS One; 2013; 8(2):e55264. PubMed ID: 23405128
[TBL] [Abstract][Full Text] [Related]
14. Adjuvating the adjuvant: facilitated delivery of an immunomodulatory oligonucleotide to TLR9 by a cationic antimicrobial peptide in dendritic cells.
Aichinger MC; Ginzler M; Weghuber J; Zimmermann L; Riedl K; Schütz G; Nagy E; von Gabain A; Schweyen R; Henics T
Vaccine; 2011 Jan; 29(3):426-36. PubMed ID: 21093498
[TBL] [Abstract][Full Text] [Related]
15. The two component adjuvant IC31® potentiates the protective immunity induced by a dengue 2 recombinant fusion protein in mice.
Bernardo L; Pavón A; Hermida L; Gil L; Valdés I; Cabezas S; Linares R; Alvarez M; Silva R; Guillén G; Nagy E; Schlick P; Guzmán MG
Vaccine; 2011 Jun; 29(25):4256-63. PubMed ID: 21447316
[TBL] [Abstract][Full Text] [Related]
16. Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose.
Aagaard C; Hoang TT; Izzo A; Billeskov R; Troudt J; Arnett K; Keyser A; Elvang T; Andersen P; Dietrich J
PLoS One; 2009 Jun; 4(6):e5930. PubMed ID: 19529771
[TBL] [Abstract][Full Text] [Related]
17. Novel protein-based pneumococcal vaccines administered with the Th1-promoting adjuvant IC31 induce protective immunity against pneumococcal disease in neonatal mice.
Olafsdottir TA; Lingnau K; Nagy E; Jonsdottir I
Infect Immun; 2012 Jan; 80(1):461-8. PubMed ID: 22025519
[TBL] [Abstract][Full Text] [Related]
18. Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial.
Suliman S; Luabeya AKK; Geldenhuys H; Tameris M; Hoff ST; Shi Z; Tait D; Kromann I; Ruhwald M; Rutkowski KT; Shepherd B; Hokey D; Ginsberg AM; Hanekom WA; Andersen P; Scriba TJ; Hatherill M;
Am J Respir Crit Care Med; 2019 Jan; 199(2):220-231. PubMed ID: 30092143
[TBL] [Abstract][Full Text] [Related]
19. A phase I, open-label trial on the safety and immunogenicity of the adjuvanted tuberculosis subunit vaccine H1/IC31® in people living in a TB-endemic area.
Hussein J; Zewdie M; Yamuah L; Bedru A; Abebe M; Dagnew AF; Chanyalew M; Yohannes AG; Ahmed J; Engers H; Doherty TM; Bang P; Kromann I; Hoff ST; Aseffa A
Trials; 2018 Jan; 19(1):24. PubMed ID: 29321075
[TBL] [Abstract][Full Text] [Related]
20. Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers.
van Dissel JT; Arend SM; Prins C; Bang P; Tingskov PN; Lingnau K; Nouta J; Klein MR; Rosenkrands I; Ottenhoff TH; Kromann I; Doherty TM; Andersen P
Vaccine; 2010 Apr; 28(20):3571-81. PubMed ID: 20226890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]